초분자의약화학 연구실

During the last ten years, our main efforts have been directed to increase the therapeutic efficacy of nanomedicine and develop the new supramolecular cancer therapy. In the nanomedicine approach, we can increase the encapsulation stability of small drug molecules and minimize protein corona formation by supramolecularly polymer/protein modification onto mesoporous silica nanoparticle. However, molecular mechanism of the interactions occurring on the interfaces between nanomaterials and proteins still remains largely unknown and furthermore there is a challenge to regulate the nanoparticle–biological interactions that provide profound impacts on cancer therapy. As an expansion of the previous research, we plan to further investigate these interactions by varying nanoparticles including biodegradable silica nanoparticle, mesorporous metal-ogranic framework, and proteins. Eventually, based on the fundamental understanding of these interactions, we will investigate the method to become closer to clinical translation of nanomedicine. In the supramolecular therapy, we showed a new paradigm in cancer therapy, drug-free cancer therapy, which can overcome the multidrug resistance, limitation of current chemotherapy. However, it still has a limitation at the selectivity to cancer and pharmacokinetics. Thus, we plan to develop tumor microenvironment responsive supramolecular therapy to increase tumor selectivity and vary molecular design of peptides to enhance pharmacokinetics. The research theme of the Ryu research group is the development of new disease therapy using supramolecular approach (Supramolecular Therapeutics). The Ryu group have developed the conventional-drug-free approach for a new anti-cancer/anti-ageing therapy, that intracellular (supramolecular) polymerization